HBL - Hadasit Bio-Holdings Past Earnings Performance
Past criteria checks 0/6
HBL - Hadasit Bio-Holdings's earnings have been declining at an average annual rate of -34.6%, while the Biotechs industry saw earnings growing at 11.1% annually. Revenues have been declining at an average rate of 105.7% per year.
Key information
-34.6%
Earnings growth rate
-34.9%
EPS growth rate
| Biotechs Industry Growth | -24.5% |
| Revenue growth rate | -105.7% |
| Return on equity | -267.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How HBL - Hadasit Bio-Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -8 | 2 | 0 |
| 31 Mar 24 | 0 | -18 | 2 | 0 |
| 31 Dec 23 | 0 | -29 | 2 | 0 |
| 30 Sep 23 | 0 | -29 | 2 | 0 |
| 30 Jun 23 | 0 | -29 | 2 | 0 |
| 31 Mar 23 | 0 | -30 | 3 | 0 |
| 31 Dec 22 | 0 | -31 | 3 | 0 |
| 30 Sep 22 | 0 | -27 | 3 | 0 |
| 30 Jun 22 | 0 | -22 | 2 | 0 |
| 31 Mar 22 | 0 | 3 | 2 | 0 |
| 31 Dec 21 | 0 | 28 | 2 | 0 |
| 30 Sep 21 | 0 | 31 | 2 | 0 |
| 30 Jun 21 | 0 | 33 | 2 | 0 |
| 31 Mar 21 | 0 | 32 | 2 | 0 |
| 31 Dec 20 | 0 | 31 | 2 | 0 |
| 30 Sep 20 | 0 | 21 | 3 | 0 |
| 30 Jun 20 | 0 | 11 | 3 | 0 |
| 31 Mar 20 | 0 | -6 | 3 | 0 |
| 31 Dec 19 | 0 | -22 | 3 | 0 |
| 30 Jun 19 | 0 | -14 | 3 | 0 |
| 31 Mar 19 | 0 | -3 | 3 | 0 |
| 31 Dec 18 | 0 | 7 | 3 | 0 |
| 30 Jun 18 | 0 | 32 | 4 | -7 |
| 31 Mar 18 | 0 | 33 | 4 | -4 |
| 31 Dec 17 | 0 | 34 | 4 | 0 |
| 30 Sep 17 | 0 | 13 | 6 | 16 |
| 30 Jun 17 | 0 | 13 | 4 | 15 |
| 31 Mar 17 | 0 | 6 | 5 | 13 |
| 31 Dec 16 | 0 | 11 | 3 | 0 |
| 30 Sep 16 | 0 | -6 | 6 | 8 |
| 30 Jun 16 | 0 | -9 | 6 | 6 |
| 31 Mar 16 | 0 | -10 | 6 | 6 |
| 31 Dec 15 | 0 | -17 | 6 | 8 |
| 30 Sep 15 | 0 | -18 | 7 | 10 |
| 30 Jun 15 | 0 | -16 | 6 | 11 |
| 31 Mar 15 | 0 | -12 | 6 | 10 |
| 31 Dec 14 | 0 | -6 | 5 | 7 |
| 30 Sep 14 | 0 | -8 | 5 | 7 |
| 30 Jun 14 | 0 | -11 | 5 | 6 |
| 31 Mar 14 | 0 | -17 | 5 | 7 |
Quality Earnings: HDST-M is currently unprofitable.
Growing Profit Margin: HDST-M is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HDST-M is unprofitable, and losses have increased over the past 5 years at a rate of 34.6% per year.
Accelerating Growth: Unable to compare HDST-M's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HDST-M is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: HDST-M has a negative Return on Equity (-267.69%), as it is currently unprofitable.